Alzheon, Inc. announced that Founder, President and CEO Martin Tolar, MD, PhD, will deliver a presentation and join a panel discussion at the Neurodegenerative Drug Development Summit on February 24th, 2021. The kick-off panel discussion at 9:10 AM ET will focus on recent progress in drug development across the industry and new research into the mechanisms driving neurodegenerative pathology, among other topics. Dr. Tolar’s presentation at 3:10 PM ET will provide an overview of Alzheon’s oral Phase 3 drug candidate, ALZ-801, which prevents formation of neurotoxic soluble amyloid oligomers that drive onset and progression of AD. As an oral small molecule drug targeting amyloid toxicity, ALZ-801 is in a class of its own, and has shown potential for robust efficacy and favorable safety in the high-risk population of patients with two copies of the apolipoprotein e4 allele (APOE4/4). With endorsement and support from the National Institute of Aging in the form of a $47 million grant, Alzheon’s Phase 3 trial of ALZ-801 will begin enrolling patients in the 2nd quarter of 2021. Alzheon’s precision medicine approach will enroll the highest-risk patient group of APOE4/4 subjects, and will incorporate the latest biomarkers to track patient benefits — p-tau blood biomarkers, hippocampal volume and cortical thickness measures, as well as tau positron emission tomography imaging in a subset of enrolled subjects.